(AOF) – Oncodesign, a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces the result of its capital increase with priority period for shareholders for an amount of approximately 2 million euros. The capital increase will result in the issue of 1.51 million new shares.
Karine Lignel, Deputy Managing Director of Oncodesign Precision Medicine, commented: “We have chosen, in 2022, to list ourselves on the stock exchange in order to allow our shareholders to benefit alongside us from the creation of value generated by the part Biotech, after the transaction carried out on Oncodesign Services, which enabled its shareholders to achieve one of the greatest stock market gains in recent years in the Health sector. Together, we aim to grow Oncodesign Precision Medicine which is already presenting two molecules in the clinic and is following its development plan.”
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
